Evotec SE (NASDAQ:EVO - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 115,762 shares traded hands during mid-day trading, a decline of 14% from the previous session's volume of 134,963 shares.The stock last traded at $3.52 and had previously closed at $3.61.
Evotec Stock Up 2.0 %
The business has a 50 day simple moving average of $4.14 and a 200-day simple moving average of $4.10. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Trading of Evotec
Several hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new position in shares of Evotec during the 4th quarter valued at approximately $27,000. CSS LLC IL bought a new position in Evotec during the fourth quarter valued at $50,000. Bank of America Corp DE increased its position in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Evotec in the fourth quarter valued at $166,000. Finally, DCF Advisers LLC lifted its position in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after buying an additional 12,816 shares during the last quarter. Institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
